The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies.
Posttransplant monitoring of anti-HLA antibodies with routine techniques gives unsatisfactory results due to a variety of technical limitations. We investigated how a new alternative technique correlates with posttransplant clinical events. A total of 313 nonselected serum samples from 136 patients were screened by an ELISA utilizing captured soluble HLA class I antigens. We observed the absence of anti-HLA antibody production in acute rejection cases responding to standard antirejection therapy. On the other hand, we showed a clear presence of these antibodies in acute rejection episodes not responding to standard therapy (P<0.0001) and in chronic rejection (P<0.001). We conclude that routine posttransplant monitoring by ELISA offers early risk assessment that is crucial for proper immunosuppression and for antirejection therapy choice.
Costa
A N
AN
Department of Clinical Medicine and Applied Biotechnology, University of Bologna, Italy.
Scolari
M P
MP
Iannelli
S
S
Buscaroli
A
A
D'Arcangelo
G L
GL
Brando
B
B
Indiveri
F
F
Savi
M
M
Borgnino
L C
LC
DeSanctis
L B
LB
Stefoni
S
S
Bonomini
V
V
D003602:Cytotoxicity, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D006084:Graft Rejection; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*
D006680:HLA Antigens; D007074:Immunoglobulin G